User login
Key clinical point: Mutations of the CCAAT/enhancer-binding protein alpha gene (CEBPA) in the basic leucine zipper domain (bZIP), even when detected as single-mutated CEBPA, were associated with favorable prognosis in patients with de novo acute myeloid leukemia (AML).
Major finding: Patients with compared to without CEBPA mutation in bZIP had a higher rate of complete remission, longer overall survival (OS), and lower cumulative incidence of relapse (all P < .001). Among patients with single-mutated CEBPA, those with CEBPA mutation in compared to out-of bZIP had a significantly longer OS (P = .008).
Study details: Findings are from a retrospective analysis of 1,028 patients with de novo AML.
Disclosures: No source of funding was identified. The authors declared no conflict of interests.
Source: Wakita S et al. Blood Adv. 2021 Aug 27. doi: 10.1182/bloodadvances.2021004292.
Key clinical point: Mutations of the CCAAT/enhancer-binding protein alpha gene (CEBPA) in the basic leucine zipper domain (bZIP), even when detected as single-mutated CEBPA, were associated with favorable prognosis in patients with de novo acute myeloid leukemia (AML).
Major finding: Patients with compared to without CEBPA mutation in bZIP had a higher rate of complete remission, longer overall survival (OS), and lower cumulative incidence of relapse (all P < .001). Among patients with single-mutated CEBPA, those with CEBPA mutation in compared to out-of bZIP had a significantly longer OS (P = .008).
Study details: Findings are from a retrospective analysis of 1,028 patients with de novo AML.
Disclosures: No source of funding was identified. The authors declared no conflict of interests.
Source: Wakita S et al. Blood Adv. 2021 Aug 27. doi: 10.1182/bloodadvances.2021004292.
Key clinical point: Mutations of the CCAAT/enhancer-binding protein alpha gene (CEBPA) in the basic leucine zipper domain (bZIP), even when detected as single-mutated CEBPA, were associated with favorable prognosis in patients with de novo acute myeloid leukemia (AML).
Major finding: Patients with compared to without CEBPA mutation in bZIP had a higher rate of complete remission, longer overall survival (OS), and lower cumulative incidence of relapse (all P < .001). Among patients with single-mutated CEBPA, those with CEBPA mutation in compared to out-of bZIP had a significantly longer OS (P = .008).
Study details: Findings are from a retrospective analysis of 1,028 patients with de novo AML.
Disclosures: No source of funding was identified. The authors declared no conflict of interests.
Source: Wakita S et al. Blood Adv. 2021 Aug 27. doi: 10.1182/bloodadvances.2021004292.